A novel type of influenza vaccine: Safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 354-362

  Wacheck, Volker ^a   Egorov, Andrej ^f   Groiss, Franz ^f   Pfeiffer, Andrea ^f   Fuereder, Thorsten ^a   Hoeflmayer, Doris ^a   Kundi, Michael ^d   Popow Kraupp, Therese ^e   Redlberger Fritz, Monika ^e   Mueller, Christian A ^b   Cinatl, Jindrich ^g   Michaelis, Martin ^g   Geiler, Janina ^g   Bergmann, Michael ^c   Romanova, Julia ^f   Roethl, Elisabeth ^f   Morokutti, Alexander ^f   Wolschek, Markus ^f   Ferko, Boris ^f   Seipelt, Joachim ^f   Dick Gudenus, Rosmarie ^f   Muster, Thomas ^f   more..

^a Departments of Clinical Pharmacology

^b Departments of Otolaryngology   (United States)

^c Salvation Army Scarborough Grace H   (Canada)

^d Centre for Public Health   (New Zealand)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Avir Green Hills Biotechnology AG   (Austria)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA NONSTRUCTURAL PROTEIN 1 INFLUENZA VIRUS H1N1 VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PLACEBO; UNCLASSIFIED DRUG; INS1 PROTEIN, INFLUENZA VIRUS; LIVE VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1 INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; VACCINATION; VIRUS REPLICATION; VIRUS STRAIN; BLOOD; DOSE RESPONSE; GENE DELETION; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; NOSE MUCUS; VIROLOGY; VIRUS SHEDDING;

ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; GENE DELETION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NASAL LAVAGE FLUID; VACCINES, ATTENUATED; VIRAL NONSTRUCTURAL PROTEINS; VIRUS SHEDDING;

EID: 75649127312     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649428     Document Type: Article

References (24)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-5096.
2. Glezen WP, Simonsen L. Commentary: benefits of influenza vaccine in US elderly. Int J Epidemiol 2006; 35:352-353.
3. 3. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-1174. (Pubitemid 41393594)
4. Simonsen L, Viboud C, Taylor R. Influenza vaccination in elderly people. Lancet 2005; 366:2086.
5. 5. Egorov A, Brandt S, Sereinig S, et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998;72:6437-6441. (Pubitemid 28323956)
6. 6. Garcia-Sastre A, Egorov A, Matassov D, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998;252:324-330. (Pubitemid 29013414)
7. 7. Ferko B, Stasakova J, Romanova J, et al. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol 2004;78:13037-13045. (Pubitemid 39507811)
8. 8. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DE Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14:461-470. (Pubitemid 32441598)
9. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006; 12:61-65.
10. 10. Proietti E, Bracci L, Puzelli S, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002; 169:375-383. (Pubitemid 34686158)
11. 11. Talon J, Salvatore M, O'Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci U S A 2000;97:4309-4314. (Pubitemid 30226129)
12. Tovey MG, Lallemand C, Thyphronitis G. Adjuvant activity of type I interferons. Biol Chem 2008;389:541-545.
13. Hale BG, Randall RE, Ortin J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008; 89:2359-2376.
14. Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate. Vaccine 2009;27: 2851-2857.
15. Wressnigg N, Shurygina AP, Wolff T, et al. Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. J Gen Virol 2009; 90:366-374.
16. 16. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000;97:6108-6113. (Pubitemid 30367531)
17. 17. Pleschka S, Jaskunas R, Engelhardt OG, Zurcher T, Palese P, Garcia-Sastre A. A plasmid-based reverse genetics system for influenza A virus. J Virol 1996;70:4188-4192. (Pubitemid 26157406)
18. 18. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23: 2943-2952. (Pubitemid 40386496)
19. World Health Organization (WHO). WHO manual on animal influenza diagnosis and surveillance (WHO/CDS/CSR/NCS/2002.5Rev.1). WHO Web site. http://www.who.int/vaccine-research/diseases/influenza/WHO-manual-on-animal- diagnosis-and-surveillance-2002-5.pdf. Published 2005. Accessed November 2008.
20. FluMist [package insert]. Gaithersburg, MD: MedImmune; 2008.
21. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-175.
22. 22. Block SL, Reisinger KS, Hultquist M, Walker RE. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007; 51:4001-4008. (Pubitemid 350057799)
23. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18:899-906.
24. 24. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355:2513-2522. (Pubitemid 44917499)